CRL (CRL) CFO Glenn Coleman receives 6,640-share equity grant at $180.71

Rhea-AI Filing Summary

Coleman Glenn reported acquisition or exercise transactions in this Form 4 filing.

Charles River Laboratories International EVP & CFO Glenn Coleman received a stock grant. On May 29, he was awarded 6,640 shares of common stock at a reference value of $180.71 per share as compensation, increasing his directly held stake to 27,752 shares.

A footnote explains that the unvested restricted stock units underlying this award will vest in equal annual installments on May 29, 2027, May 29, 2028, May 29, 2029, and May 29, 2030, subject to the applicable award terms.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Coleman Glenn

Role EVP & Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	6,640	$180.71	$1.20M

Holdings After Transaction: Common Stock — 27,752 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares granted: 6,640 shares Grant reference price: $180.71 per share Shares held after transaction: 27,752 shares

3 metrics

Shares granted 6,640 shares Non-derivative common stock award on May 29, 2026

Grant reference price $180.71 per share Price per share for the 6,640-share award

Shares held after transaction 27,752 shares Direct common stock ownership following the grant

Key Terms

restricted stock units, vest, grant, award, or other acquisition, non-derivative

4 terms

restricted stock units financial

"Unvested restricted stock units annually ratably vest on May 29, 2027..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vest financial

"Unvested restricted stock units annually ratably vest on May 29, 2027..."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

non-derivative financial

"transaction_type": "non-derivative""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coleman Glenn

(Last) (First) (Middle)

C/O CHARLES RIVER LABORATORIES

251 BALLARDVALE ST

(Street)

WILMINGTON MASSACHUSETTS 01887

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/29/2026		A		6,640(1)	A	$180.71	27,752	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Unvested restricted stock units annually ratably vest on May 29, 2027; May 29, 2028; May 29, 2029; and May 29, 2030.

	/s/ Glenn Coleman	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CRL executive Glenn Coleman report?

Glenn Coleman, EVP & Chief Financial Officer of Charles River Laboratories, reported an acquisition of shares as compensation. He received 6,640 shares of common stock, recorded at $180.71 per share, in a grant classified as a non-derivative award acquisition.

How many CRL shares does Glenn Coleman hold after this Form 4 filing?

After the reported grant, Glenn Coleman directly holds 27,752 shares of Charles River Laboratories common stock. This total reflects the newly awarded 6,640 shares in addition to his prior holdings, as shown in the post-transaction ownership figure in the filing.

What is the nature of the CRL shares acquired by Glenn Coleman?

The acquisition is a grant or award of common stock, not an open-market purchase. The filing describes it as a non-derivative award acquisition, with unvested restricted stock units that vest annually over future dates, indicating compensation-related equity rather than a market trade.

At what price per share was Glenn Coleman’s CRL stock grant recorded?

The 6,640-share grant to Glenn Coleman was recorded at $180.71 per share. This value serves as the reference price for the award, as disclosed in the transaction price per share field for the non-derivative common stock acquisition in the filing.

How do Glenn Coleman’s CRL restricted stock units vest over time?

The unvested restricted stock units vest in equal annual installments on May 29, 2027, May 29, 2028, May 29, 2029, and May 29, 2030. This schedule spreads vesting over four consecutive years, consistent with long-term equity compensation structures for senior executives.